Innoviva (INVA) Revenue (QoQ) (2011 - 2026)
Innoviva (INVA) Revenue (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,931.71% |
| Dec 31, 2025 | -99.63% |
| Sep 30, 2025 | 195.88% |
| Jun 30, 2025 | 13.15% |
| Mar 31, 2025 | 7,076.68% |
| Dec 31, 2024 | -99.54% |
| Sep 30, 2024 | 167.18% |
| Jun 30, 2024 | 3,905.53% |
| Mar 31, 2024 | 63.22% |
| Dec 31, 2023 | -99.32% |
| Sep 30, 2023 | 7,845.63% |
| Jun 30, 2023 | 53.06% |
| Mar 31, 2023 | 75.74% |
| Dec 31, 2022 | -99.60% |
| Sep 30, 2022 | 6,363.88% |
| Jun 30, 2022 | 84.63% |
| Mar 31, 2022 | 124.97% |
| Dec 31, 2021 | -99.65% |
| Sep 30, 2021 | 10,279.33% |
| Jun 30, 2021 | 74.39% |